Approach to smoking cessation in the patient with vascular disease

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 2, 2011, Pages 91-102

  Ratchford, Elizabeth V ^a   Black III, James H ^b  

^a Johns Hopkins   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CANNABINOID 1 RECEPTOR ANTAGONIST; CLONIDINE; DOFETILIDE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; PLACEBO; RIMONABANT; TARANABANT; VARENICLINE;

ACUPUNCTURE; APPLICATION SITE REACTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL EVALUATION; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COUGHING; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HICCUP; HUMAN; HYPNOSIS; INDIGESTION; INSOMNIA; JAW DISEASE; LACRIMATION DISORDER; LEG PAIN; LIFESTYLE MODIFICATION; MATERNAL SMOKING; MENTAL DISEASE; MONOTHERAPY; MOUTH DISCOMFORT; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE DISEASE; PATIENT COUNSELING; RASH; RHINORRHEA; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; SMOKING HABIT; SNEEZING; THROAT IRRITATION; TOBACCO DEPENDENCE; UNPLEASANT DREAM; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIVID DREAM; WEIGHT GAIN; XEROSTOMIA;

EID: 79955938868     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-011-0109-x     Document Type: Article

References (44)

1. R Doll R Peto J Boreham I Sutherland 2004 Mortality in relation to smoking: 50 years' observations on male British doctors BMJ 328 1519 15213107 10.1136/bmj.38142.554479.AE
2. Vital signs: Current cigarette smoking among adults aged∈≥∈ 18 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:1135-1140.
3. NL Benowitz 2010 Nicotine addiction N Engl J Med 362 2295 2303 20554984 10.1056/NEJMra0809890 1:CAS:528:DC%2BC3cXnvVakurw%3D This is a thorough review of the pathophysiology and pharmacology of nicotine addiction.
4. SA Schroeder KE Warner 2010 Don't forget tobacco N Engl J Med 363 201 204 20647196 10.1056/NEJMp1003883 1:CAS:528:DC%2BC3cXptVKisLk%3D
5. SA Schroeder 2005 What to do with the patient who smokes JAMA 294 482 487 16046655 10.1001/jama.294.4.482 1:CAS:528:DC%2BD2MXms1ygsbk%3D (Pubitemid 41124181)
6. AT Hirsch ZJ Haskal NR Hertzer, et al. 2006 ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J Am Coll Cardiol 47 e2 192 10.1016/j.jacc.2005.10.009
7. JF Price PI Mowbray AJ Lee, et al. 1999 Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study Eur Heart J 20 344 53 10206381 10.1053/euhj.1998.1194 1:STN:280:DyaK1M3itFahsA%3D%3D (Pubitemid 29103732)
8. GR Fowkes E Housley RA Riemersma, et al. 1992 Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study Am J Epidemiol 135 331 340 1550087 1:STN:280:DyaK387pslGkuw%3D%3D
9. GD Smith MJ Shipley G Rose 1990 Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study Circulation 82 1925 31 2242518 1:STN:280:DyaK3M%2FlsFaksA%3D%3D
10. AW Gardner 1996 The effect of cigarette smoking on exercise capacity in patients with intermittent claudication Vasc Med 1 3 181 186 9546936 1:STN:280:DyaK1c7nsl2qtQ%3D%3D (Pubitemid 26402979)
11. CRG Quick LT Cotton 1982 The measured effect of stopping smoking on intermittent claudication Br J Surg 69 Suppl S24 S26 7082968 10.1002/bjs.1800691309 (Pubitemid 12096147)
12. EM Willigendael JA Teijink ML Bartelink, et al. 2005 Smoking and the patency of lower extremity bypass grafts: a meta-analysis J Vasc Surg 42 67 74 16012454 10.1016/j.jvs.2005.03.024 (Pubitemid 40966078)
13. LH Bonati J Ederle DJ McCabe, et al. 2009 Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial Lancet Neurol 8 10 908 17 19717347 10.1016/S1474-4422(09)70227-3
14. FA Lederle DB Nelson AM Joseph 2003 Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review J Vasc Surg 38 329 334 12891116 10.1016/S0741-5214(03)00136-8 (Pubitemid 41123258)
15. AR Brady SG Thompson FG Fowkes, et al. 2004 Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance Circulation 110 1 16 21 15210603 10.1161/01.CIR.0000133279.07468.9F (Pubitemid 38880128)
16. SZ Goldhaber 2010 Risk factors for venous thromboembolism J Am Coll Cardiol 56 1 1 7 20620709 10.1016/j.jacc.2010.01.057
17. JW Olin 2000 Thromboangiitis obliterans (Buerger's disease) N Engl J Med 343 864 9 10995867 10.1056/NEJM200009213431207 1:STN:280:DC%2BD3cvjvFenug%3D%3D
18. HM Johnson LK Gossett ME Piper, et al. 2010 Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial J Am Coll Cardiol 55 18 1988 95 20236788 10.1016/j.jacc.2010.03. 002 1:CAS:528:DC%2BC3cXns1Gisb8%3D This study is the first to look at the long-term effects of smoking cessation and continued smoking on endothelial function; the findings may in part explain the observed reduction in cardiovascular risk with smoking cessation.
19. JH Black 2010 Evidence base and strategies for successful smoking cessation J Vasc Surg 51 1529 1537 20223623 10.1016/j.jvs.2009.10.124 This recent article provides an excellent overview of smoking cessation from the perspective of a vascular specialist.
20. SC Smith J Allen SN Blair, et al. 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update Circulation 113 19 2363 2372 16702489 10.1161/ CIRCULATIONAHA.106.174516 (Pubitemid 43947981)
21. S Tonstad 2009 Smoking cessation: how to advise the patient Heart 95 19 1635 1640 19752210 10.1136/hrt.2008.154476 This article provides practical advice on how to approach the patient.
22. Fiore MC, Bailey WC, Cohen SF, et al.: Treating tobacco use and dependence: Clinical practice guideline. Rockville, MD: Dept of Health and Human Services; 2000. June.
23. Fiore MC, Jaén CR, Baker TB, et al: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. This is the most recent authoritative Clinical Practice Guideline.
24. Drugs for tobacco dependence. Treat Guidel Med Lett 2008, 6:61-66.
25. LF Stead R Perera C Bullen, et al. 2008 Nicotine replacement therapy for smoking cessation Cochrane Database Syst Rev 23 1 CD000146
26. P Hajek R West J Foulds, et al. 1999 Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler Arch Intern Med 159 2033 2038 10510989 10.1001/archinte.159.17.2033 1:CAS:528:DyaK1MXms12mtrw%3D (Pubitemid 29453591)
27. State cigarette excise tax rates & rankings. Available at http://www.tobaccofreekids.org/research/factsheets/pdf/0097.pdf. Accessed October 2010.
28. RA Schnoll F Patterson EP Wileyto, et al. 2010 Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial Ann Intern Med 152 3 144 151 20124230
29. S Shiffman CM Dresler P Hajek, et al. 2002 Efficacy of a nicotine lozenge for smoking cessation Arch Intern Med 162 11 1267 76 12038945 10.1001/archinte.162.11.1267 1:CAS:528:DC%2BD38XkvF2nt7s%3D (Pubitemid 34595033)
30. Safety of smoking cessation drugs. Med Lett 2009, 51(1319):65.
31. RD Hurt DPL Sachs ED Glover, et al. 1997 A comparison of sustained-release bupropion and placebo for smoking cessation N Engl J Med 337 17 1195 1202 9337378 10.1056/NEJM199710233371703 1:CAS:528:DyaK2sXntVaqsLc%3D (Pubitemid 27454451)
32. DE Jorenby SJ Leischlow MA Nides, et al. 1999 A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation N Engl J Med 340 685 691 10053177 10.1056/NEJM199903043400903 1:CAS:528: DyaK1MXhvFWhsLk%3D (Pubitemid 29110752)
33. S Tonstad C Farsang G Klaene, et al. 2003 Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Eur Heart J 24 10 946 955 12714026 10.1016/S0195-668X(03)00003-4 1:CAS:528:DC%2BD3sXjtFWms70%3D (Pubitemid 36559988)
34. GD Garrison SE Dugan 2009 Varenicline: a first-line treatment option for smoking cessation Clin Ther 31 3 463 491 19393839 10.1016/j.clinthera.2009.03. 021 1:CAS:528:DC%2BD1MXls1Snu7Y%3D This article provides a thorough review of the literature on the pharmacologic properties, therapeutic efficacy, and tolerability of varenicline for smoking cessation.
35. D Gonzales SI Rennard M Nides, et al. 2006 Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial JAMA 296 47 55 16820546 10.1001/jama.296.1.47 1:CAS:528:DC%2BD28Xms1OrtLw%3D
36. JE Jorenby JT Hays NA Rigotti, et al. 2006 Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial JAMA 296 56 63 16820547 10.1001/jama.296.1.56 1:CAS:528:DC%2BD28Xms1OrtL0%3D
37. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Syst Rev 2008: CD006103.
38. NA Rigotti AL Pipe NL Benowitz, et al. 2010 Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial Circulation 121 2 221 9 20048210 10.1161/CIRCULATIONAHA.109. 869008 1:CAS:528:DC%2BC3cXktVCnsg%3D%3D This is a key study demonstrating the safety and efficacy of varenicline in patients with cardiovascular disease.
39. Saul S. F.A.A. bans antismoking drug, citing side effects. The New York Times, May 22, 2008.
40. Federal Motor Carrier Safety Administration. Statement from Administrator. Available at http://www.fmcsa.dot.gov/statement-5-23-08.htm? printer=true. Accessed October 2010.
41. S Tonstad P Tønnesen P Hajek, et al. 2006 Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 296 1 64 71 16820548 10.1001/jama.296.1.64 1:CAS:528:DC%2BD28Xms1OrtLo%3D
42. P Tønnesen 2009 Smoking cessation: How compelling is the evidence? A review Health Policy 91 Suppl 1 S15 25 19735853 10.1016/S0168-8510(09)70004-1
43. MF Morrison P Cessay I Gantz, et al. 2010 Randomized, controlled, double-blind trial of taranabant for smoking cessation Psychopharmacology (Berl) 209 3 245 253 10.1007/s00213-010-1790-2 1:CAS:528:DC%2BC3cXisFWisb8%3D
44. K Cahill M Ussher 2007 Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation Cochrane Database Syst Rev 18 3 CD005353